News >

AHCT Consolidation Improves PFS in Younger Patients With Mantle Cell Lymphoma

Caroline Seymour
Published: Thursday, Jan 17, 2019

James N. Gerson, MD

James N. Gerson, MD

Within 6 months of receiving induction chemotherapy, consolidation treatment with autologous hematopoietic cell transplantation (AHCT) correlated with a significant improvement in progression-free survival (PFS) in younger, fit patients with mantle cell lymphoma (MCL), according to a retrospective analysis published in the Journal of Clinical Oncology.

“With this and other well-designed prospective trials, as well as with well-validated predictive biomarkers, clinicians will be better able to provide a more refined, risk-adapted approach to first-line management of MCL,” concluded Gerson et al.
Gerson J, Handorf E, Villa D, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. [published online ahead of print January 7, 2019]. J Clin Oncol. doi: 10.1200/JCO.18.00690.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x